Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
RED-BLOOD-CELL GLUTATHIONE LEVELS BEFORE AND DURING TREATMENT WITH NEOADJUVANT CHEMOTHERAPY CISPLATIN 5-FLUOROURACIL IN PATIENTS WITH HEAD AND NECK SQUAMOUS-CELL CARCINOMA/
Autore:
MASSAADMASSADE L; DOMENGE C; RONGEAT S; HASSOUN L; LEGROS MH; ROPERS J; JANOT F; PARISE O; GOUYETTE A;
Indirizzi:
INSERM,U490,45 RUE ST PERES F-75270 PARIS 06 FRANCE INST GUSTAVE ROUSSY,DEPT PHARMACOTOXICOL & PHARMACOGENET,CNRS,URA 147F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,DEPT CHIRURG CERVICOFACIALE & ORL F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,DEPT STAT BIOMED F-94805 VILLEJUIF FRANCE
Titolo Testata:
Anticancer research
fascicolo: 1A, volume: 18, anno: 1998,
pagine: 283 - 288
SICI:
0250-7005(1998)18:1A<283:RGLBAD>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
CANCER-PATIENTS; CISPLATIN; RESISTANCE; 5-FLUOROURACIL; FLUOROURACIL; CARBOPLATIN; THERAPY; SYSTEMS;
Keywords:
GLUTATHIONE; HEAD AND NECK SQUAMOUS CARCINOMA; CHEMOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
21
Recensione:
Indirizzi per estratti:
Citazione:
L. Massaadmassade et al., "RED-BLOOD-CELL GLUTATHIONE LEVELS BEFORE AND DURING TREATMENT WITH NEOADJUVANT CHEMOTHERAPY CISPLATIN 5-FLUOROURACIL IN PATIENTS WITH HEAD AND NECK SQUAMOUS-CELL CARCINOMA/", Anticancer research, 18(1A), 1998, pp. 283-288

Abstract

The purpose of this study was to find out whether the glutathione (GSH), in red blood cells could predict the response to neoadjuvant chemotherapy cisplatin/5-fluorouracil (CDDP/5-FU) in patients with head andneck squamous cell carcinoma (HNSCC). Three courses of induction chemotherapy with CDDP/5-FU were administered and followed by surgery and radiotherapy or radiotherapy alone, in 51 patients with HNSCC. GSH wasmeasured by spectrophotometry in red blood cell, before any treatment(Sample I: SI), after each course of chemotherapy (S2, S3, S4). Our results showed that GSH was the same at diagnosis in patients with complete or partial response (OR) compared to those with stable or progressive disease (NR). With regard to evolution of the GSH during the 3 courses of CT a significant difference was found between courses (S2: 5.06 +/- 0.35 vs S4 = 3.61 +/- 0.4 mu mol/g haemoglobin, p < 0.05). Whenwe separated our patients into OR and NR, a significant difference was found over the 3 courses of chemotherapy for GSH content. Non responder patients showed decreased GSH content at the end of the treatment,(S2: 5 +/- 0.5 vs S4: 2.2 +/- 0.4 mu mol/g haemoglobin, p < 0.05) while OR were stable. In conclusion, red blood cell GSH seems to have no early predictive value for chemoresponse to neoadjuvant chemotherapy CDDP/5-FU in HNSCC.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 04:21:37